 Cardiovascular Agents
"Cardiovascular Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume.
| Descriptor ID |
D002317
|
| MeSH Number(s) |
D27.505.954.411
|
| Concept/Terms |
Cardiovascular Agents- Cardiovascular Agents
- Agents, Cardiovascular
- Cardiovascular Drugs
- Drugs, Cardiovascular
|
Below are MeSH descriptors whose meaning is more general than "Cardiovascular Agents".
Below are MeSH descriptors whose meaning is more specific than "Cardiovascular Agents".
This graph shows the total number of publications written about "Cardiovascular Agents" by people in this website by year, and whether "Cardiovascular Agents" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 1 | 2 | | 1997 | 1 | 1 | 2 | | 1999 | 0 | 1 | 1 | | 2000 | 1 | 2 | 3 | | 2003 | 1 | 0 | 1 | | 2004 | 0 | 1 | 1 | | 2005 | 0 | 1 | 1 | | 2006 | 1 | 1 | 2 | | 2007 | 1 | 0 | 1 | | 2008 | 3 | 0 | 3 | | 2009 | 2 | 5 | 7 | | 2010 | 0 | 4 | 4 | | 2011 | 4 | 3 | 7 | | 2012 | 1 | 4 | 5 | | 2013 | 3 | 0 | 3 | | 2014 | 5 | 2 | 7 | | 2015 | 6 | 2 | 8 | | 2016 | 8 | 2 | 10 | | 2017 | 6 | 1 | 7 | | 2018 | 6 | 4 | 10 | | 2019 | 5 | 1 | 6 | | 2020 | 1 | 2 | 3 | | 2021 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Cardiovascular Agents" by people in Profiles.
-
Glasgow RE, Knoepke CE, Magid D, Grunwald GK, Glorioso TJ, Waughtal J, Marrs JC, Bull S, Ho PM. The NUDGE trial pragmatic trial to enhance cardiovascular medication adherence: study protocol for a randomized controlled trial. Trials. 2021 Aug 11; 22(1):528.
-
Simon ST, Kini V, Levy AE, Ho PM. Medication adherence in cardiovascular medicine. BMJ. 2021 08 11; 374:n1493.
-
McDonald M, Virani S, Chan M, Ducharme A, Ezekowitz JA, Giannetti N, Heckman GA, Howlett JG, Koshman SL, Lepage S, Mielniczuk L, Moe GW, O'Meara E, Swiggum E, Toma M, Zieroth S, Anderson K, Bray SA, Clarke B, Cohen-Solal A, D'Astous M, Davis M, De S, Grant ADM, Grzeslo A, Heshka J, Keen S, Kouz S, Lee D, Masoudi FA, McKelvie R, Parent MC, Poon S, Rajda M, Sharma A, Siatecki K, Storm K, Sussex B, Van Spall H, Yip AMC. CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction. Can J Cardiol. 2021 04; 37(4):531-546.
-
Gurin MI, Beyer SE, Weinberg M, Parikh SA, Armstrong EJ, Albaghdadi MS, Aronow HD, Carroll BJ, Yeh R, Secemsky EA. Health Care Utilization Following Inpatient Femoropopliteal Revascularization With Drug-Coated Balloon Angioplasty: A Nationwide Cohort Analysis. J Endovasc Ther. 2021 Apr; 28(2):246-254.
-
Nicholls SJ, Schwartz GG, Buhr KA, Ginsberg HN, Johansson JO, Kalantar-Zadeh K, Kulikowski E, Toth PP, Wong N, Sweeney M, Ray KK. Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study. Cardiovasc Diabetol. 2021 01 07; 20(1):13.
-
Abraham WT, Psotka MA, Fiuzat M, Filippatos G, Lindenfeld J, Mehran R, Ambardekar AV, Carson PE, Jacob R, Januzzi JL, Konstam MA, Krucoff MW, Lewis EF, Piccini JP, Solomon SD, Stockbridge N, Teerlink JR, Unger EF, Zeitler EP, Anker SD, O'Connor CM. Standardized definitions for evaluation of heart failure therapies: scientific expert panel from the Heart Failure Collaboratory and Academic Research Consortium. Eur J Heart Fail. 2020 12; 22(12):2175-2186.
-
Lewis CV, Taylor WR. Intestinal barrier dysfunction as a therapeutic target for cardiovascular disease. Am J Physiol Heart Circ Physiol. 2020 12 01; 319(6):H1227-H1233.
-
Goel E, Erwin M, Cawthon CV, Schaff C, Fedor N, Rayl T, Wilson O, Christians U, Register TC, Geary RL, Saul J, Yazdani SK. Pre-Clinical Investigation of Keratose as an Excipient of Drug Coated Balloons. Molecules. 2020 Mar 31; 25(7).
-
Giannopoulos S, Jeon-Slaughter H, Kahlon RS, Tejani I, Baskar A, Banerjee S, Armstrong EJ. Comparative 12-Month Outcomes of Drug-Coated Balloon Versus Non-Drug-Coated Balloon Revascularization Strategy in Chronic Limb-Threatening Ischemia: Results From the XLPAD Registry. Cardiovasc Revasc Med. 2020 10; 21(10):1276-1284.
-
Cantu D, Jawaid O, Kokkinidis D, Giannopoulos S, Valle JA, Waldo SW, Singh GD, Armstrong EJ. Outcomes of Drug-Coated Balloon Angioplasty vs. Conventional Balloon Angioplasty for Endovascular Treatment of Common Femoral Artery Atherosclerotic Disease. Cardiovasc Revasc Med. 2020 07; 21(7):867-874.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|